X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications, national advocacy events and grassroots initiative, Voters for Cures. He also helped found and currently co-chairs The PRIDE Umbrella, PhRMA’s employee resource group for LGBTQ+ colleagues. Before joining PhRMA in 2015, Andrew worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; and served on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists, singer with The Gay Men’s Chorus of Washington, and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Recent Posts

Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines

By Andrew Powaleny  |    September 12, 2022
As we’ve discussed on this blog before, timely reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA) is critical to sustaining the U.S. Food and Drug...   Read More

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

By Andrew Powaleny  |    August 16, 2022
Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around...   Read More

The Patient Perspective: Government price-setting harms patients

By Andrew Powaleny  |    July 22, 2022
Unfortunately, policymakers are again looking for bumper-sticker answers to the health care affordability challenges many Americans face, ignoring real commonsense solutions in exchange for flawed...   Read More

ICYMI: Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

By Andrew Powaleny  |    July 14, 2022
A new report released by the U.S. Centers for Disease Control and Prevention (CDC) shows the number of antimicrobial-resistant (AMR) infections rose dramatically during the first year of the COVID-19...   Read More

ICYMI: Antimicrobial resistance spotlighted as growing public health threat

By Andrew Powaleny  |    July 6, 2022
On June 28, PhRMA Chief Operating Officer Lori Reilly joined Executive Director of CARB-X, Kevin Outterson, Esq., and Interim Secretariat Lead of the Global Antimicrobial Resistance (AMR) R&D Hub,...   Read More

Recognizing LGBTQ+ Pride in biopharmaceutical science

By Andrew Powaleny  |    June 9, 2022
June is Pride Month and, like many across the country, we look forward to celebrating the importance of equality and reminding ourselves to continually seek opportunities to make our society more...   Read More

Report: More than 500 medicines in development to treat disorders of the blood

By Andrew Powaleny  |    May 18, 2022
Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...   Read More

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

By Andrew Powaleny  |    May 13, 2022
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...   Read More

The accelerated approval pathway: Helping patients with serious or life-threatening diseases

By Andrew Powaleny  |    March 17, 2022
Today, the House Energy & Commerce Committee’s Subcommittee on Health will meet to discuss policy proposals to “encourage innovation and improve oversight” regarding medical innovation. This hearing...   Read More

4 things to know about biopharmaceutical efforts to fight cancer

By Andrew Powaleny  |    February 24, 2022
A recent study published in Nature is a profound reminder of how far we’ve come in the fight against cancer. Authors of the study, which examined the long-term effects of CAR-T cell therapy,...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates